Selective Serotonin 5-HT3 Receptor Antagonists for Postoperative Nausea and Vomiting: Are They All the Same?

Overview

Journal CNS Drugs

Specialties Neurology
Pharmacology

Date 2005 Mar 3

PMID 15740177

Citations 33

Authors

Tong J Gan

Affiliations

Soon will be listed here.

Abstract

Selective serotonin 5-HT(3) receptor antagonists have proven safe and effective for the management of postoperative nausea and vomiting. Dolasetron, granisetron, ondansetron and tropisetron selectively and competitively bind to 5-HT(3) receptors, blocking serotonin binding at vagal afferents in the gut and in the regions of the CNS involved in emesis, including the chemoreceptor trigger zone and the nucleus tractus solitarii. Despite their shared mechanism of action, 5-HT(3) receptor antagonists have different chemical structures and exhibit differences in receptor binding affinity, dose response and duration of effect. Furthermore, although dolasetron, granisetron, ondansetron and tropisetron are all extensively metabolised by the cytochrome P450 (CYP) system, different components of this system predominate in the metabolism of each of these agents. Hence, although these agents are considered equally effective in the overall population, their pharmacokinetic and pharmacodynamic differences may explain the variability in individual responses to these drugs. This review discusses the pharmacological profiles of dolasetron, granisetron, ondansetron and tropisetron, and the clinical implications of differences in their profiles.

Citing Articles

Population pharmacokinetic analysis of transdermal granisetron in healthy Chinese and Caucasian volunteers.

Li J, Hu P, Zhou L, Nagahama F, Chen R Front Pharmacol. 2023; 14:1154026.

PMID: 37435499 PMC: 10330959. DOI: 10.3389/fphar.2023.1154026.

Comparison of Intravenous Granisetron and Ondansetron on Hemodynamics and Sensory Motor Block After Spinal Anaesthesia With Hyperbaric Bupivacaine in Patients Undergoing Elective Surgery: A Randomized Double-Blind Study.

Shukla U, Kumar M, Gautam K, Yadav J Cureus. 2023; 15(3):e36383.

PMID: 37090391 PMC: 10115694. DOI: 10.7759/cureus.36383.

A Randomised Controlled Trial to Compare the Effect of Ramosetron and Ondansetron in Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Gynaecological Procedures.

Das S, Kumar A, Gupta A, Kumar A Cureus. 2022; 14(9):e29200.

PMID: 36258972 PMC: 9569150. DOI: 10.7759/cureus.29200.

5-HT receptor antagonists decrease the prevalence of postoperative delirium in older patients undergoing orthopedic lower limb surgery.

Shin H, Yoon J, Na H Perioper Med (Lond). 2021; 10(1):51.

PMID: 34876219 PMC: 8653581. DOI: 10.1186/s13741-021-00222-3.

Serotonin as a Mitogen in the Gastrointestinal Tract: Revisiting a Familiar Molecule in a New Role.

Shah P, Park C, Shaughnessy M, Cowles R Cell Mol Gastroenterol Hepatol. 2021; 12(3):1093-1104.

PMID: 34022423 PMC: 8350061. DOI: 10.1016/j.jcmgh.2021.05.008.

References

Arcioni R, della Rocca M, Romano S, Romano R, Pietropaoli P, Gasparetto A . Ondansetron inhibits the analgesic effects of tramadol: a possible 5-HT(3) spinal receptor involvement in acute pain in humans. Anesth Analg. 2002; 94(6):1553-7, table of contents. DOI: 10.1097/00000539-200206000-00033. View

Boike S, Ilson B, Zariffa N, Jorkasky D . Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. Am J Health Syst Pharm. 1997; 54(10):1172-6. DOI: 10.1093/ajhp/54.10.1172. View

Tamminga W, Wemer J, Oosterhuis B, Weiling J, Wilffert B, de Leij L . CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol. 1999; 55(3):177-84. DOI: 10.1007/s002280050615. View

Cieslak G, Watcha M, Phillips M, Pennant J . The dose-response relation and cost-effectiveness of granisetron for the prophylaxis of pediatric postoperative emesis. Anesthesiology. 1996; 85(5):1076-85. DOI: 10.1097/00000542-199611000-00016. View

Benedict C, Arbogast R, Martin L, Patton L, Morrill B, Hahne W . Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol. 1996; 28(1):53-9. DOI: 10.1097/00005344-199607000-00009. View

Wilson A, Diemunsch P, Lindeque B, Scheinin H, Helbo-Hansen H, Kroeks M . Single-dose i.v. granisetron in the prevention of postoperative nausea and vomiting. Br J Anaesth. 1996; 76(4):515-8. DOI: 10.1093/bja/76.4.515. View

Kovac A, OConnor T, Pearman M, Kekoler L, Edmondson D, Baughman V . Efficacy of repeat intravenous dosing of ondansetron in controlling postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled multicenter trial. J Clin Anesth. 1999; 11(6):453-9. DOI: 10.1016/s0952-8180(99)00067-7. View

Kees F, Farber L, Bucher M, Mair G, Morike K, Grobecker H . Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers. Br J Clin Pharmacol. 2001; 52(6):705-7. PMC: 2014558. DOI: 10.1046/j.0306-5251.2001.01512.x. View

Andrews P, Bhandari P, Davey P, Bingham S, Marr H, Blower P . Are all 5-HT3 receptor antagonists the same?. Eur J Cancer. 1992; 28A Suppl 1:S2-6. DOI: 10.1016/0959-8049(92)90628-f. View

10.

Vickers A, Fischer V, Connors M, Biggi W, Heitz F, Baldeck J . Biotransformation of the antiemetic 5-HT3 antagonist tropisetron in liver and kidney slices of human, rat and dog with a comparison to in vivo. Eur J Drug Metab Pharmacokinet. 1996; 21(1):43-50. DOI: 10.1007/BF03190277. View

11.

Hof R, Hof A, Novosel D, Zierhut W . Antiarrhythmic and hemodynamic effects of tropisetron in anesthetized rabbits. J Cardiovasc Pharmacol. 1993; 22(3):499-505. DOI: 10.1097/00005344-199309000-00023. View

12.

Tramer M . A rational approach to the control of postoperative nausea and vomiting: evidence from systematic reviews. Part I. Efficacy and harm of antiemetic interventions, and methodological issues. Acta Anaesthesiol Scand. 2001; 45(1):4-13. DOI: 10.1034/j.1399-6576.2001.450102.x. View

13.

Graczyk S, McKenzie R, Kallar S, Hickok C, Melson T, Morrill B . Intravenous dolasetron for the prevention of postoperative nausea and vomiting after outpatient laparoscopic gynecologic surgery. Anesth Analg. 1997; 84(2):325-30. DOI: 10.1097/00000539-199702000-00015. View

14.

Tsui S, Ng K, Wong L, Tang G, Pun T, Yang J . Prevention of postoperative nausea and vomiting in gynaecological laparotomies: a comparison of tropisetron and ondansetron. Anaesth Intensive Care. 1999; 27(5):471-6. DOI: 10.1177/0310057X9902700506. View

15.

Koriech O . Fluoxetine treatment comprises the antiemetic efficacy of ondansetron in cancer patients. Clin Oncol (R Coll Radiol). 1995; 7(6):371-2. DOI: 10.1016/s0936-6555(05)80007-x. View

16.

KORTTILA K, Clergue F, Leeser J, Feiss P, Olthoff D, Wessel P . Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study. Acta Anaesthesiol Scand. 1997; 41(7):914-22. DOI: 10.1111/j.1399-6576.1997.tb04809.x. View

17.

Sung Y . Risks and benefits of drugs used in the management of postoperative nausea and vomiting. Drug Saf. 1996; 14(3):181-97. DOI: 10.2165/00002018-199614030-00005. View

18.

Kuryshev Y, Brown A, Wang L, Benedict C, Rampe D . Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Exp Ther. 2000; 295(2):614-20. View

19.

Herrstedt J . Development of antiemetic therapy in cancer patients. Acta Oncol. 1995; 34(5):637-40. DOI: 10.3109/02841869509094040. View

20.

Upward J, Arnold B, Link C, Pierce D, Allen A, Tasker T . The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist. Eur J Cancer. 1990; 26 Suppl 1:S12-5. View